Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Stock Report

| More

Health Canada Approves Biocon and Mylan's Ogivri™, the First Trastuzumab Biosimilar

Posted On: 2019-05-24 10:40:10

Biocon Ltd. and Mylan N.V. has announced that Health Canada has approved Mylan's Ogivri™ (trastuzumab), a biosimilar to Herceptin®1 (trastuzumab) co-developed with Biocon, for the treatment of HER2-overexpressing breast cancer and metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma).

Ogivri is the first trastuzumab biosimilar approved in Canada and the second biosimilar from Biocon and Mylan's joint portfolio approved in the market. Mylan plans to launch the product this quarter and anticipates potentially being the first company to offer a trastuzumab biosimilar in Canada.

Dr Christiane Hamacher, CEO, Biocon Biologics said, "We are pleased to enable access to Ogivri, a high quality biosimilar trastuzumab co-developed and manufactured by Biocon as an affordable treatment option for HER2- positive breast and gastric cancer patients in Canada. The Health Canada approval granted to Ogivri, will pave the way for its commercialization by our partner Mylan. Thousands of patients in Europe, India and key emerging markets are benefitting from our biosimilar trastuzumab. Biocon Biologics is committed to address unmet patient needs through its high quality, affordable biologics, globally."

Mylan's Chief Commercial Officer Tony Mauro commented, "As a global leader in the development of complex products, including biosimilar medicines, we're pleased to reach this approval milestone for Ogivri and the opportunity to bring this important treatment option to market for Canadian patients with HER2-positive breast and gastric cancers. We look forward to continuing our reimbursement discussions with the Canadian Agency for Drugs and Technologies in Health (CADTH) and the Pan-Canadian Pharmaceutical Alliance (pCPA} to ensure that patients have access to Ogivri."

Approval by Health Canada was based on robust data from structural and functional characterization using multiple orthogonal techniques, nonclinical studies and pharmacokinetic evaluation in healthy subjects and patients and a safety, efficacy and immunogenicity study in relevant patient populations, which compared Ogivri to Herceptin. The data demonstrated that Ogivri is highly similar to Herceptin with no clinically meaningful differences in terms of efficacy, safety, purity and potency.

Biocon and Mylan's trastuzumab biosimilar is currently approved in more than 65 countries around the world, including the U.S.

Shares of BIOCON LTD. was last trading in BSE at Rs.510.7 as compared to the previous close of Rs. 519.6. The total number of shares traded during the day was 144554 in over 3535 trades.

The stock hit an intraday high of Rs. 526.95 and intraday low of 509.05. The net turnover during the day was Rs. 74890459.

1 Herceptin® is a product of Hoffmann-La Roche Ltd.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

IndiGo to connect Dammam with Delhi w.e.f. March 10, 2020

Union Bank of India bags prestigious IBA Award

Elpro Join Hands with Shiksha Seva Foundation to Empower Girl Child

CREDAI and SBI organise three day Double Assurance Realty Expo

HCG Hospital Redefines cancer diagnostics with the first Digital PET CT scanner in Karnataka

Varroc Showcases the Roadmap for the Future of Mobility at Auto Components Expo

IndiGo now connects Mumbai-Kathmandu and Bangalore-Jeddah

Airtel and Nokia to collaborate on Industry 4.0 applications for enterprises

IndiGo launches Hindi website to strengthen its regional reach

Reliance Infrastructure Ltd Q3 FY20 consolidated PAT up 18% at Rs. 346 crores

Glenmark's consolidated Net Profit rises by 64% to Rs. 1,908.39 Mn. in Q3 FY 2019-20

Reliance Power Ltd Q3 FY20 PAT at Rs. 49 crore

Panacea Biotec Ltd announces financial results for period ended Dec 31, 2019

Nila Infrastructures Ltd reports earnings for Q3 FY2020

Shyam Century Ferrous Limited updates on credit rating

Akme Star Housing Finance Ltd opens branch in Chennai

Ashoka Buildcon Ltd receives LOA from NHAI for Tumkur-Shivamogga road project

Poddar Housing and Development Ltd launches 'Poddar RIVIERA'

USFDA completes inspection at Granules India's Hyderabad facility

Swelect Energy Systems Ltd Board approves interim dividend of Rs. 1.25 for 2019-20

Simplex Infra announces unaudited Q3FY20 results

Sadbhav Engineering Ltd - Key Financial Highlights

Supply of some components affected due to Coronovirus issue in China - Hero MotoCorp Ltd

Ador Welding Ltd Board declares Interim Dividend of Rs. 6.50 for FY20

Indo Rama Synthetics India Ltd announces Q3 FY20 results

Rushil Decor Ltd Q3 net profit zooms to Rs. 9.34 crore

Vipul Organics Ltd Q3 FY20 net profit climbs to Rs. 1.64 crore

Sreeleathers Ltd Q3 net profit drops to Rs. 6.65 crore

Intense Technologies Ltd Q3 FY20 consolidated PAT at Rs.1.29 crore

The Sandur Manganese & Iron Ores Ltd Q3 consolidated net profit slides to Rs. 19.70 crore

RAJ Oil Mills Ltd Q3 net profit slips to Rs. 0.83 crore

PDS Multinational Fashions Ltd Q3 FY20 consolidated PAT at Rs. 10.43 crore

Savera Industries Ltd posts Rs. 1.77 crore PAT in 3rd quarter of FY20

GRM Overseas Ltd consolidated Q3 net profit rises to Rs. 4.75 crore

SEYA Industries Ltd Q3 net profit falls to Rs. 7.09 crore

GSS Infotech Ltd posts Rs. 1.69 crore consolidated PAT in Q3

KDDL Ltd reports consolidated PAT of Rs. 3.18 crore in Q3

Asian Tea & Exports Ltd posts consolidated PAT of Rs. 1.52 crore in 3rd quarter

S P Apparels Ltd Q3 consolidated PAT slumps to Rs. 1.89 crore

Samrat Pharmachem Ltd posts Rs. 0.47 crore net profit in Q3 FY20

ADOR Welding Ltd consolidated Q3 net profit drops QoQ, increases YoY

RPP Infra Projects Ltd posts consolidated PAT of Rs. 6.66 crore in Q3

Nikhil Adhesives Ltd reports Rs. 1.72 crore PAT in Q3 FY2019-20

Sandesh Ltd Board declares Interim Dividend of Rs. 5 for 2019-20

Lahoti Overseas Ltd board approves interim dividend of Rs. 0.30

Jindal Stainless (Hisar) Limited reports Q3 PAT at Rs 60 crore

Alufluoride Ltd defers stopping of Vizag Aluminium Fluoride Plant

Emerald Leasing Finance & Investment Company Ltd posts Q3 FY20 consolidated PAT of Rs. 0.42 crore

Mahalaxmi Rubtech Ltd reports lower consolidated net profit of Rs. 0.79 crore in Q3

Sandesh Ltd Q3 FY2019-20 consolidated net profit drops QoQ to Rs. 16.05 crore







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019